Report: China rounds up GlaxoSmithKline staffers in corruption probe

John Carroll FierceBiotech News

Sanofi, Novartis, GlaxoSmithKline reportedly circling India’s Elder Pharma

Tracy Staton It's early days for Elder Pharmaceuticals' sell-or-not analysis. But the Indian media antennae are out for the latest tremor of news. Today, the Economic Times ...

GlaxoSmithKline CEO’s M&A aim: Sell more, buy less

Carly Helfand As it prepares for a crop of new treatments to hit the market, GlaxoSmithKline is joining the ranks of Big Pharma companies that no longer want to be quite so big. FiercePharma ...

GlaxoSmithKline will be very picky about new deals

John Carroll GlaxoSmithKline CEO Andrew Witty tells Reuters' Ben Hirschler that the company's M&A team has stepped away from doing many new deals right now as the company ...

GlaxoSmithKline reveals mixed results for diabetes contender in ‘crowded area’

Ryan McBride As has often been the case with GlaxoSmithKline's GLP-1 candidate albiglutide, a late-stage study in diabetics taking the drug and metformin offered some upbeat and ...

GlaxoSmithKline fuels VC fund as part of rare diseases blitz

Ryan McBride GlaxoSmithKline is backing another venture fund. The London-based drug giant has committed 17.5 million euros for a VC vehicle focused on rare diseases startups in Europe, ...

GlaxoSmithKline slams brakes on trial of MS drug linked to data scandal

Ryan McBride GlaxoSmithKline has stopped development of an experimental drug for multiple sclerosis after a preclinical study turned out to contain "misrepresentations" in ...

GlaxoSmithKline investigates alleged data fraud involving R&D lab staffers in China

Ryan McBride GlaxoSmithKline has launched a probe of a research study involving its employees from a research lab in Shanghai, China. FierceBiotech News

Akebia snags $41M financing in anemia-drug race with GlaxoSmithKline, others

Ryan McBride Today the company disclosed a $ 41 million Series C financing amid plans for a Phase IIb study later this year for AKB-6548, which is among a potential blockbuster class ...

GlaxoSmithKline grabs PhII rheumatoid arthritis drug in $579M MorphoSys deal

John Carroll GSK is paying about $ 28 million of that upfront and will take over all further R&D and commercialization efforts. MorphoSys snags a double-digit royalty stream from ...

GlaxoSmithKline nabs key FDA approvals for two melanoma drugs

Tracy Staton Two of GlaxoSmithKline's hopes for 2013 are now fulfilled: The company won FDA approval for its melanoma treatments Tafinlar and Mekinist, both targeted at patients ...

GlaxoSmithKline gains FDA OK on two genetically targeted skin cancer drugs

John Carroll In an important win for GlaxoSmithKline's R&D division, the FDA today announced that it has approved a pair of genetically targeted melanoma drugs, dabrafenib and ...
Page 5 of 7« First...34567
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS